Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase™: Unified list based on international collaborative work

Ayako Suzuki, Raul J. Andrade, Einar Bjornsson, M. Isabel Lucena, William M. Lee, Nancy A. Yuen, Christine M. Hunt, James W. Freston

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Background: Challenges exist in the clinical diagnosis of drug-induced liver injury (DILI) and in obtaining information on hepatotoxicity in humans. Objective: (i) To develop a unified list that combines drugs incriminated in well vetted or adjudicated DILI cases from many recognized sources and drugs that have been subjected to serious regulatory actions due to hepatotoxicity; and (ii) to supplement the drug list with data on reporting frequencies of liver events in the WHO individual case safety report database (VigiBase ). Data Sources and Extraction: (i) Drugs identified as causes of DILI at three major DILI registries; (ii) drugs identified as causes of drug-induced acute liver failure (ALF) in six different data sources, including major ALF registries and previously published ALF studies; and (iii) drugs identified as being subjected to serious governmental regulatory actions due to their hepatotoxicity in Europe or the US were collected. The reporting frequency of adverse events was determined using VigiBase, computed as Empirical Bayes Geometric Mean (EBGM) with 90% confidence interval for two customized terms, 'overall liver injury' and 'ALF'. EBGM of ≥2 was considered a disproportional increase in reporting frequency. The identified drugs were then characterized in terms of regional divergence, published case reports, serious regulatory actions, and reporting frequency of 'overall liver injury' and 'ALF' calculated from VigiBase. Data Synthesis: After excluding herbs, supplements and alternative medicines, a total of 385 individual drugs were identified; 319 drugs were identified in the three DILI registries, 107 from the six ALF registries (or studies) and 47 drugs that were subjected to suspension or withdrawal in the US or Europe due to their hepatotoxicity. The identified drugs varied significantly between Spain, the US and Sweden. Of the 319 drugs identified in the DILI registries of adjudicated cases, 93.4% were found in published case reports, 1.9% were suspended or withdrawn due to hepatotoxicity and 25.7%were also identified in the ALF registries/studies. In VigiBase, 30.4% of the 319 drugs were associated with disproportionally higher reporting frequency of 'overall liver injury' and 83.1% were associated with at least one reported case of ALF. Conclusions: This newly developed list of drugs associated with hepatotoxicity and the multifaceted analysis on hepatotoxicity will aid in causality assessment and clinical diagnosis of DILI and will provide a basis for further characterization of hepatotoxicity.

Original languageEnglish (US)
Pages (from-to)503-522
Number of pages20
JournalDrug Safety
Volume33
Issue number6
DOIs
StatePublished - 2010

Fingerprint

Liver
Acute Liver Failure
Chemical and Drug Induced Liver Injury
Pharmaceutical Preparations
Registries
Information Storage and Retrieval
Wounds and Injuries
Complementary Therapies
Sweden
Causality
Spain
Suspensions
Research Design
Databases

Keywords

  • Liver-disorders, drug-induced
  • Liver-failure, drug-induced
  • Liver-injury, drug-induced
  • Postmarketing-surveillance

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Toxicology

Cite this

Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase™ : Unified list based on international collaborative work. / Suzuki, Ayako; Andrade, Raul J.; Bjornsson, Einar; Lucena, M. Isabel; Lee, William M.; Yuen, Nancy A.; Hunt, Christine M.; Freston, James W.

In: Drug Safety, Vol. 33, No. 6, 2010, p. 503-522.

Research output: Contribution to journalArticle

Suzuki, Ayako ; Andrade, Raul J. ; Bjornsson, Einar ; Lucena, M. Isabel ; Lee, William M. ; Yuen, Nancy A. ; Hunt, Christine M. ; Freston, James W. / Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase™ : Unified list based on international collaborative work. In: Drug Safety. 2010 ; Vol. 33, No. 6. pp. 503-522.
@article{875197f306294f0ba69d352a02dc1b80,
title = "Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase™: Unified list based on international collaborative work",
abstract = "Background: Challenges exist in the clinical diagnosis of drug-induced liver injury (DILI) and in obtaining information on hepatotoxicity in humans. Objective: (i) To develop a unified list that combines drugs incriminated in well vetted or adjudicated DILI cases from many recognized sources and drugs that have been subjected to serious regulatory actions due to hepatotoxicity; and (ii) to supplement the drug list with data on reporting frequencies of liver events in the WHO individual case safety report database (VigiBase ™). Data Sources and Extraction: (i) Drugs identified as causes of DILI at three major DILI registries; (ii) drugs identified as causes of drug-induced acute liver failure (ALF) in six different data sources, including major ALF registries and previously published ALF studies; and (iii) drugs identified as being subjected to serious governmental regulatory actions due to their hepatotoxicity in Europe or the US were collected. The reporting frequency of adverse events was determined using VigiBase™, computed as Empirical Bayes Geometric Mean (EBGM) with 90{\%} confidence interval for two customized terms, 'overall liver injury' and 'ALF'. EBGM of ≥2 was considered a disproportional increase in reporting frequency. The identified drugs were then characterized in terms of regional divergence, published case reports, serious regulatory actions, and reporting frequency of 'overall liver injury' and 'ALF' calculated from VigiBase™. Data Synthesis: After excluding herbs, supplements and alternative medicines, a total of 385 individual drugs were identified; 319 drugs were identified in the three DILI registries, 107 from the six ALF registries (or studies) and 47 drugs that were subjected to suspension or withdrawal in the US or Europe due to their hepatotoxicity. The identified drugs varied significantly between Spain, the US and Sweden. Of the 319 drugs identified in the DILI registries of adjudicated cases, 93.4{\%} were found in published case reports, 1.9{\%} were suspended or withdrawn due to hepatotoxicity and 25.7{\%}were also identified in the ALF registries/studies. In VigiBase™, 30.4{\%} of the 319 drugs were associated with disproportionally higher reporting frequency of 'overall liver injury' and 83.1{\%} were associated with at least one reported case of ALF. Conclusions: This newly developed list of drugs associated with hepatotoxicity and the multifaceted analysis on hepatotoxicity will aid in causality assessment and clinical diagnosis of DILI and will provide a basis for further characterization of hepatotoxicity.",
keywords = "Liver-disorders, drug-induced, Liver-failure, drug-induced, Liver-injury, drug-induced, Postmarketing-surveillance",
author = "Ayako Suzuki and Andrade, {Raul J.} and Einar Bjornsson and Lucena, {M. Isabel} and Lee, {William M.} and Yuen, {Nancy A.} and Hunt, {Christine M.} and Freston, {James W.}",
year = "2010",
doi = "10.2165/11535340-000000000-00000",
language = "English (US)",
volume = "33",
pages = "503--522",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase™

T2 - Unified list based on international collaborative work

AU - Suzuki, Ayako

AU - Andrade, Raul J.

AU - Bjornsson, Einar

AU - Lucena, M. Isabel

AU - Lee, William M.

AU - Yuen, Nancy A.

AU - Hunt, Christine M.

AU - Freston, James W.

PY - 2010

Y1 - 2010

N2 - Background: Challenges exist in the clinical diagnosis of drug-induced liver injury (DILI) and in obtaining information on hepatotoxicity in humans. Objective: (i) To develop a unified list that combines drugs incriminated in well vetted or adjudicated DILI cases from many recognized sources and drugs that have been subjected to serious regulatory actions due to hepatotoxicity; and (ii) to supplement the drug list with data on reporting frequencies of liver events in the WHO individual case safety report database (VigiBase ™). Data Sources and Extraction: (i) Drugs identified as causes of DILI at three major DILI registries; (ii) drugs identified as causes of drug-induced acute liver failure (ALF) in six different data sources, including major ALF registries and previously published ALF studies; and (iii) drugs identified as being subjected to serious governmental regulatory actions due to their hepatotoxicity in Europe or the US were collected. The reporting frequency of adverse events was determined using VigiBase™, computed as Empirical Bayes Geometric Mean (EBGM) with 90% confidence interval for two customized terms, 'overall liver injury' and 'ALF'. EBGM of ≥2 was considered a disproportional increase in reporting frequency. The identified drugs were then characterized in terms of regional divergence, published case reports, serious regulatory actions, and reporting frequency of 'overall liver injury' and 'ALF' calculated from VigiBase™. Data Synthesis: After excluding herbs, supplements and alternative medicines, a total of 385 individual drugs were identified; 319 drugs were identified in the three DILI registries, 107 from the six ALF registries (or studies) and 47 drugs that were subjected to suspension or withdrawal in the US or Europe due to their hepatotoxicity. The identified drugs varied significantly between Spain, the US and Sweden. Of the 319 drugs identified in the DILI registries of adjudicated cases, 93.4% were found in published case reports, 1.9% were suspended or withdrawn due to hepatotoxicity and 25.7%were also identified in the ALF registries/studies. In VigiBase™, 30.4% of the 319 drugs were associated with disproportionally higher reporting frequency of 'overall liver injury' and 83.1% were associated with at least one reported case of ALF. Conclusions: This newly developed list of drugs associated with hepatotoxicity and the multifaceted analysis on hepatotoxicity will aid in causality assessment and clinical diagnosis of DILI and will provide a basis for further characterization of hepatotoxicity.

AB - Background: Challenges exist in the clinical diagnosis of drug-induced liver injury (DILI) and in obtaining information on hepatotoxicity in humans. Objective: (i) To develop a unified list that combines drugs incriminated in well vetted or adjudicated DILI cases from many recognized sources and drugs that have been subjected to serious regulatory actions due to hepatotoxicity; and (ii) to supplement the drug list with data on reporting frequencies of liver events in the WHO individual case safety report database (VigiBase ™). Data Sources and Extraction: (i) Drugs identified as causes of DILI at three major DILI registries; (ii) drugs identified as causes of drug-induced acute liver failure (ALF) in six different data sources, including major ALF registries and previously published ALF studies; and (iii) drugs identified as being subjected to serious governmental regulatory actions due to their hepatotoxicity in Europe or the US were collected. The reporting frequency of adverse events was determined using VigiBase™, computed as Empirical Bayes Geometric Mean (EBGM) with 90% confidence interval for two customized terms, 'overall liver injury' and 'ALF'. EBGM of ≥2 was considered a disproportional increase in reporting frequency. The identified drugs were then characterized in terms of regional divergence, published case reports, serious regulatory actions, and reporting frequency of 'overall liver injury' and 'ALF' calculated from VigiBase™. Data Synthesis: After excluding herbs, supplements and alternative medicines, a total of 385 individual drugs were identified; 319 drugs were identified in the three DILI registries, 107 from the six ALF registries (or studies) and 47 drugs that were subjected to suspension or withdrawal in the US or Europe due to their hepatotoxicity. The identified drugs varied significantly between Spain, the US and Sweden. Of the 319 drugs identified in the DILI registries of adjudicated cases, 93.4% were found in published case reports, 1.9% were suspended or withdrawn due to hepatotoxicity and 25.7%were also identified in the ALF registries/studies. In VigiBase™, 30.4% of the 319 drugs were associated with disproportionally higher reporting frequency of 'overall liver injury' and 83.1% were associated with at least one reported case of ALF. Conclusions: This newly developed list of drugs associated with hepatotoxicity and the multifaceted analysis on hepatotoxicity will aid in causality assessment and clinical diagnosis of DILI and will provide a basis for further characterization of hepatotoxicity.

KW - Liver-disorders, drug-induced

KW - Liver-failure, drug-induced

KW - Liver-injury, drug-induced

KW - Postmarketing-surveillance

UR - http://www.scopus.com/inward/record.url?scp=77952847965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952847965&partnerID=8YFLogxK

U2 - 10.2165/11535340-000000000-00000

DO - 10.2165/11535340-000000000-00000

M3 - Article

C2 - 20486732

AN - SCOPUS:77952847965

VL - 33

SP - 503

EP - 522

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 6

ER -